All In Biotech

Drug Trial Radar · NCT04640545

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

79

Actual

Start

May 12, 2020

Primary completion

Aug 19, 2024

Study completion Aug 19, 2024

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors

Conditions

  • Advanced Melanoma

Interventions

  • LBL-007Drug

    LBL-007 will be administered intravenously every two weeks (Q2W) .

  • ToripalimabDrug

    Toripalimab Injection will be administered by intravenously (Q2W) .

  • Axitinib TabletsDrug

    Axitinib Tablets On-demand administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjcects with adverse events and serious adverse eventsTime frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
  2. Maximum tolerated dose (MTD)Time frame: During the first two Cycles(each cycle is 14 days)
  3. Dose-limiting toxicities (DLT)Time frame: During the first two Cycles(each cycle is 14 days)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.